Global Research PartnershipsCreate free account
Industry Collaboration Index

Sector Award · Health and life sciences · 2026

Pharmaceuticals and Therapeutics: the winner and finalists

10 finalist partnerships, chosen from 5,599 eligible university and company partnerships in the open record. The winner is listed first; the other finalists follow in alphabetical order of university. The winner in each category is the finalist with the highest partnership score (volume of joint work 40%, years active 30%, field-weighted citation impact 30%) in the frozen Edition 1 record. No panel, nomination or payment plays any part. Winners were announced with the index at 05:30 BST, Thursday 15 October 2026, after the corrections and opt-out window closed at 17:00 BST on Tuesday 13 October.

All award categoriesThe Pharmaceuticals and Therapeutics sector index
★

Winner · partnership score 93.6, the highest in the category

Université Paris-Saclay×Merck & Co. (MSD)

France · company based in United States · 56 joint works in the sector · active 5 of 5 years · field-weighted citation impact 5.36
MH
Marc HumbertAcademic co-author · Université Paris-Saclay · 10 joint works in the partnership · ORCID
AC
Alexandra G. CornellIndustry co-author · Merck & Co. (MSD) · 4 joint works in the partnership
“Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death” (2025, 154 citations)
◆

Cornell University×Eli Lilly

United States · company based in United States · 46 joint works in the sector · active 5 of 5 years · field-weighted citation impact 4.74
AD
Alexander Edward Dela Cruz DrilonAcademic co-author · Cornell University · 12 joint works in the partnership · ORCID
VS
Victoria SoldatenkovaIndustry co-author · Eli Lilly · 4 joint works in the partnership
“Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial” (2022, 449 citations)
◆

Harvard University×Roche

United States · company based in Switzerland · 64 joint works in the sector · active 5 of 5 years · field-weighted citation impact 4.17
LA
Lloyd Paul AielloAcademic co-author · Harvard University · 3 joint works in the partnership · ORCID
UL
Ulrich F. O. LuhmannIndustry co-author · Roche · 3 joint works in the partnership · ORCID
“Rationale of Basic and Cellular Mechanisms Considered in Updating the Staging System for Diabetic Retinal Disease” (2024, 11 citations)
◆

Heidelberg University×Boehringer Ingelheim

Germany · company based in Germany · 84 joint works in the sector · active 5 of 5 years · field-weighted citation impact 3.35
BK
Bernhard Karl KrämerAcademic co-author · Heidelberg University · 5 joint works in the partnership · ORCID
MM
Michaela MattheusIndustry co-author · Boehringer Ingelheim · 8 joint works in the partnership · ORCID
“Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes” (2023, 7 citations)
◆

Kindai University×Bristol-Myers Squibb

Japan · company based in United States · 35 joint works in the sector · active 5 of 5 years · field-weighted citation impact 4.29
TM
Tetsuya MitsudomiAcademic co-author · Kindai University · 8 joint works in the partnership · ORCID
JN
Jaclyn NeelyIndustry co-author · Bristol-Myers Squibb · 5 joint works in the partnership · ORCID
“Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer” (2025, 45 citations)
◆

Queen Mary University of London×Merck & Co. (MSD)

United Kingdom · company based in United States · 65 joint works in the sector · active 5 of 5 years · field-weighted citation impact 3.87
PS
Peter SchmidAcademic co-author · Queen Mary University of London · 16 joint works in the partnership
VK
Vassiliki KarantzaIndustry co-author · Merck & Co. (MSD) · 14 joint works in the partnership · ORCID
“Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer” (2022, 1,194 citations)
◆

Universidad de Salamanca×Johnson & Johnson

Spain · company based in United States · 53 joint works in the sector · active 5 of 5 years · field-weighted citation impact 3.77
MM
María‐Victoria MateosAcademic co-author · Universidad de Salamanca · 38 joint works in the partnership · ORCID
RK
Rachel KobosIndustry co-author · Johnson & Johnson · 12 joint works in the partnership
“Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE” (2021, 146 citations)
◆

Université Laval×Edwards Lifesciences

Canada · company based in United States · 41 joint works in the sector · active 5 of 5 years · field-weighted citation impact 4.30
PP
Philippe PîbarotAcademic co-author · Université Laval · 35 joint works in the partnership · ORCID
YZ
Yanglu ZhaoIndustry co-author · Edwards Lifesciences · 6 joint works in the partnership · ORCID
“Evolution and Prognostic Impact of Cardiac Damage After Aortic Valve Replacement” (2022, 178 citations)
◆

University of Groningen×AstraZeneca

Netherlands · company based in United Kingdom · 97 joint works in the sector · active 5 of 5 years · field-weighted citation impact 3.54
HH
Hiddo J.L. HeerspinkAcademic co-author · University of Groningen · 50 joint works in the partnership · ORCID
CS
C. David SjöströmIndustry co-author · AstraZeneca · 18 joint works in the partnership · ORCID
“A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy” (2021, 417 citations)
◆

University of Mannheim×Boehringer Ingelheim

Germany · company based in Germany · 36 joint works in the sector · active 5 of 5 years · field-weighted citation impact 4.54
MB
Martina BrueckmannAcademic co-author · University of Mannheim · 2 joint works in the partnership · ORCID
SH
Samina Ajaz HussainIndustry co-author · Boehringer Ingelheim · 5 joint works in the partnership · ORCID
“Survodutide for the Treatment of Obesity” (2024, 34 citations)

Partnership score: volume of joint work 40%, years active 30%, field-weighted citation impact 30% (shrunk toward 1.0 when evidence is thin). Joint works count half where the only company author also holds a post at the university. The named researchers co-wrote the cited paper and represent a wider team. Full rules.